Lenalidomide in the context of complex karyotype or interrupted treatment: Case reviews of del(5q)MDS patients with unexpected responses

Annals of Hematology

Volumn 86, Issue 2, 2007, Pages 133-137

  Giagounidis, Aristoteles A N ^a   Haase, Sabine ^a   Heinsch, Michael ^a   Göhring, Gudrun ^b   Schlegelberger, Brigitte ^b   Aul, Carlo ^a  

^a ST JOHANNES HOSPITAL   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Case studies; Del(5q)MDS; Lenalidomide; Myelodysplastic syndromes; Transfusion dependent

Indexed keywords

ANTIHISTAMINIC AGENT; CYTARABINE; LENALIDOMIDE; PREDNISONE; RETINOIC ACID;

5Q- SYNDROME; ADULT; AGED; BLOOD TRANSFUSION; CHROMOSOME ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOPENIA; DRUG DOSE REDUCTION; DRUG RESPONSE; DRUG WITHDRAWAL; ERYTHEMA; ERYTHROCYTE TRANSFUSION; FEMALE; HUMAN; KARYOTYPE; LOW DRUG DOSE; MALE; MEDICAL RECORD REVIEW; METAPHASE; NEUTROPENIA; PATHOGENESIS; PRIORITY JOURNAL; REMISSION; REVIEW; SCALP PRURITUS; SKIN PRURITUS; THROMBOCYTOPENIA; TREATMENT DURATION;

ADULT; AGED; CHROMOSOME DELETION; FEMALE; HUMANS; KARYOTYPING; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; THALIDOMIDE; TREATMENT OUTCOME;

EID: 33845692628     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-006-0217-y     Document Type: Review

References (17)

1. Bartlett JB, Dredge K, Dalgleish AG (2004) The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Cancer 4:314-322
2. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C (1982) Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 51:189-199
3. Dewald GW, Davis MP, Pierre RV, O'Fallon JR, Hoagland HC (1985) Clinical characteristics and prognosis of 50 patients with a myeloproliferative syndrome and deletion of part of the long arm of chromosome 5. Blood 66:189-197
4. Dredge K, Horsfall R, Robinson SP, Zhang LH, Lu L, Tang Y, Shirley MA, Muller G, Schafer P, Stirling D, Dalgleish AG, Bartlett JB (2005) Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro. Microvasc Res 69:56-63
5. Giagounidis AA, Germing U, Haase S, Hildebrandt B, Schlegelberger B, Schoch C, Wilkens L, Heinsch M, Willems H, Aivado M, Aul C (2004) Clinical, morphological, cytogenetic, and prognostic features of patients with myelodysplastic syndromes and del(5q) including band q31. Leukemia 18:113-119
6. Giagounidis AA, Germing U, Strupp C, Hildebrandt B, Heinsch M, Aul C (2005) Prognosis of patients with del(5q) MDS and complex karyotype and the possible role of lenalidomide in this patient subgroup. Ann Hematol 84:569-571
7. Giagounidis AA, Germing U, Wainscoat JS, Boultwood J, Aul C (2004) The 5q- syndrome. Hematology 9:271-277
8. Giagounidis AA, Haase S, Germing U, Schlegelberger B, Wilkens L, Busche G, Kreipe HH, Wysk J, Grips KH, Grabenhorst U, Rothmann F, Lubbert M, Ganser A, Aivado M, Heinsch M, Aul C (2005) Treatment of myelodysplastic syndrome with isolated del(5q) including bands q31-q33 with a combination of all-trans-retinoic acid and tocopherol-alpha: A phase II study. Ann Hematol 84:389-394
9. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, Sanz M, Vallespi T, Hamblin T, Oscier D, Ohyashiki K, Toyama K, Aul C, Mufti G, Bennett J (1997) International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89:2079-2088
10. List A, Dewald G, Bennett J, Giagounidis A, Raza A, Feldman E, Powell B, Greenberg P, Thomas D, Stone R, Reeder C, Wride K, Patin J, Schmidt M, Zeldis J, Knight R (2006) Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 355:1456-1465
11. List A, Kurtin S, Roe DJ, Buresh A, Mahadevan D, Fuchs D, Rimsza L, Heaton R, Knight R, Zeldis JB (2005) Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 352:549-557
12. Malcovati L, Porta MG, Pascutto C, Invernizzi R, Boni M, Travaglino E, Passamonti F, Arcaini L, Maffioli M, Bernasconi P, Lazzarino M, Cazzola M (2005) Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: A basis for clinical decision making. J Clin Oncol 23:7594-7603
13. Mannone L, Gardin C, Quarre MC, Bernard JF, Vassilieff D, Ades L, Park S, Vaultier S, Hamza F, Beyne-rauzy MO, Cheze S, Giraudier S, Agape P, Legros L, Voillat L, Dreyfus F, Fenaux P (2006) High-dose darbepoetin alpha in the treatment of anaemia of lower risk myelodysplastic syndrome results of a phase II study. Br J Haematol 133:513-519
14. Raza A, List A, Bennett J, Dewald G, Feldman F, Reeves J, Shadduck J, Zeldis J, Knight R (2005) Lenalidomide (CC5013)-induced red blood cell (RBC) transfusion-independence (TI) responses in low-/int-1 risk patients with myelodysplastic syndromes (MDS): Results of the multicenter MDS 002 study. Leukemia Research 29 (suppl 1):S70
15. Stadler M, Germing U, Kliche KO, Josten KM, Kuse R, Hofmann WK, Schrezenmeier H, Novotny J, Anders O, Eimermacher H, Verbeek W, Kreipe HH, Heimpel H, Aul C, Ganser A (2004) A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromes. Leukemia 18:460-465
16. Van den Berghe H, Cassiman JJ, David G, Fryns JP, Michaux JL, Sokal G (1974) Distinct haematological disorder with deletion of long arm of no. 5 chromosome. Nature 251:437-438
17. Vardiman JW, Harris NL, Brunning RD (2002) The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 100:2292-2302